Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 17 June 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
In the Life Sciences business, sales volumes of organic acids and food-additive formulations increased, primarily in overseas markets, and revised selling prices also contributed. In the Electronic Materials business, sales of ultrahigh-purity colloidal silica for the semiconductor market, primarily for AI applications, remained strong. As demand is expected to exceed expectations and sales expansion is expected to continue in the second half, the company will revise upward its full-year consolidated earnings forecasts.
Loss on disposal of fixed assets: ¥131.356 million. Loss on sale of fixed assets: —.
| Item | Details |
|---|---|
| Net Sales | ¥85,800 million → ¥93,000 million（+8.4%） |
| Operating profit | ¥24,300 million → ¥28,000 million（+15.2%） |
| Ordinary income | ¥24,500 million → ¥28,100 million（+14.7%） |
| Profit attributable to owners of the parent | ¥19,200 million → ¥21,900 million（+14.1%） |
| Net income per share | 181.48 Yen/sen → 206.99 Yen/sen（+14.1%） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 17 June 2026 |
| Previous-period results | Net Sales ¥76,926 million / Operating profit ¥18,850 million / Ordinary income ¥19,573 million / Profit attributable to owners of the parent ¥14,311 million / Net income per share ¥135.28 |
| Reason for the revision | In the Life Sciences business, sales volumes of organic acids and food-additive formulations increased, primarily in overseas markets, and revised selling prices also contributed. In the Electronic Materials business, sales of ultrahigh-purity colloidal silica for the semiconductor market, primarily for AI applications, remained strong. As demand is expected to exceed expectations and sales expansion is expected to continue in the second half, the company will revise upward its full-year consolidated earnings forecasts. |
| Details and amount of extraordinary loss | Loss on disposal of fixed assets: ¥131.356 million. Loss on sale of fixed assets: —. |
| Dividend forecast revision | No change (whether the dividend forecast has been revised from the most recently announced forecast: No) |
| Consolidated / non-consolidated | Consolidated |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.During the interim period, sales volumes of organic acids and food-additive formulations increased, primarily overseas, in the Life Sciences business, and revised selling prices also contributed. In the Electronic Materials business, sales of ultrahigh-purity colloidal silica for the semiconductor market, primarily for AI applications, were strong, and the company expects demand and sales growth to continue in the second half.